Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis

Glenn Wortmann*, Michael Zapor, Roseanne Ressner, Susan Fraser, Josh Hartzell, Joseph Pierson, Amy Weintrob, Alan Magill

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

135 Scopus citations


Treatment options for cutaneous leishmaniasis in the United States are problematic because the available products are either investigational, toxic, and/or of questionable effectiveness. A retrospective review of patients receiving liposomal amphotericin B through the Walter Reed Army Medical Center for the treatment of cutaneous leishmaniasis during 2007-2009 was conducted. Twenty patients who acquired disease in five countries and with five different strains of Leishmania were treated, of whom 19 received a full course of treatment. Sixteen (84%) of 19 experienced a cure with the initial treatment regimen. Three patients did not fully heal after an initial treatment course, but were cured with additional dosing. Acute infusion-related reactions occurred in 25% and mild renal toxicity occurred in 45% of patients. Although the optimum dosing regimen is undefined and the cost and toxicity may limit widespread use, liposomal amphotericin B is a viable treatment alternative for cutaneous leishmaniasis.

Original languageEnglish
Pages (from-to)1028-1033
Number of pages6
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number5
StatePublished - Nov 2010
Externally publishedYes


Dive into the research topics of 'Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis'. Together they form a unique fingerprint.

Cite this